Over the past year, Hengrui, China’s largest pharma company, has received half-a-dozen approvals from the FDA, giving global sales at the generic- and innovative-drugs manufacturer a boost—and increasing confidence at home, where drug-contamination scares have left patients skeptical about the industry. Revenue in the first half of 2018 grew 22%, to $1.12 billion. Hengrui is also China’s market leader in oncological treatments, where demand is growing fast as the population grays. Its new-drug pipeline should help growth average 26% over the next two years.
Zhou Yun Shu
|Revenues ($M) (Past 12 Months)||$2,305|
|Profits ($M) (Past 12 Months)||$547|
|Market Value as of Oct. 10, 2018 ($M)||$30,922|